SuperworthEnliven Therapeutics shares outstanding ELVN
Diluted shares outstanding, averaged over each quarter, from 2019.
- Latest quarter, to Jun 30, 2026
- 66.2M
- On a year earlier
- +27.0%
- more shares
Enliven Therapeutics had 66.2M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 27.0% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 62.2M | +25% |
| FY2024 | 49.9M | +21% |
| FY2023 | 41.1M | +1153% |
| FY2022 | 3.3M | −50% |
| FY2021 | 6.6M | +50% |
| FY2020 | 4.4M | +2404% |
| FY2019 | 175.6K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 66.2M | +27% | |
| Q1 FY26 | 62.8M | +25% | |
| Q4 FY25 | 62.2M | +25% | |
| Q3 FY25 | 62.1M | +29% | |
| Q2 FY25 | 52.1M | +8% | |
| Q1 FY25 | 50.1M | +19% | |
| Q4 FY24 | 49.9M | +21% | |
| Q3 FY24 | 48.3M | +18% | |
| Q2 FY24 | 48.1M | +17% | |
| Q1 FY24 | 42M | +127% | |
| Q4 FY23 | 41.1M | +1153% | |
| Q3 FY23 | 41M | +1171% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Enliven Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.